Evaluation of Serum Antibodies as Correlates of Protection Against Norovirus Infection and Disease
Authors:
- Savannah L MillerSMSavannah L Miller
- W Zane BillingsWBW Zane Billings
- Murphy JohnMJMurphy John
- Hayley HemmeHHHayley Hemme
- Robert L AtmarRARobert L Atmar
- David I BernsteinDBDavid I Bernstein
- Ye ShenYSYe Shen
- Amy K WinterAWAmy K Winter
- Katia KoelleKKKatia Koelle
- Benjamin A LopmanBLBenjamin A Lopman
- Andreas HandelAHAndreas Handel
Open Access
- 20 April 2026
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (2) , 220-228
Abstract
Background: Norovirus is a major cause of acute gastroenteritis. Several vaccines are in development. Identifying a reliable immunological correlate of protection (CoP) would aid vaccine development and evaluation; however, no strong CoP has been established to date. Methods: We evaluated the relationships between prechallenge genogroup I, genotype 1 (GI.1) and GII.4 norovirus antibodies and clinical outcomes in two human vaccine-challenge studies. We analyzed genotype-specific histo-blood group antigen blocking titers, serum IgA and IgG, and total antibody ELISA. We used Bayesian regression models to assess relationships between antibody levels and protection against infection, illness, and disease severity. Results: Associations between antibody titers and protection were generally weak, and varied by genotype and vaccination status. GI.1 antibodies showed the strongest relationships, particularly among vaccinated participants, whereas naturally acquired GI.1 antibodies in unvaccinated individuals were weakly or not associated with protection. In contrast, GII.4 antibodies exhibited weak and inconsistent relationships among vaccinated participants, while unvaccinated participants showed only modest and more stable positive associations. Conclusions: Currently measured serum antibodies do not provide reliable and robust estimates of protection against norovirus clinical outcomes in all settings. Immune markers beyond serum antibody titers should be evaluated to identify more robust correlates of protection for norovirus.Keywords
Funding Information
- Norges Idrettshøgskole (GM146612)
- Norges Idrettshøgskole (R01GM124280)
This publication has 42 references indexed in Scilit:
- Correlates of Protection Against Respiratory Syncytial Virus Infection in InfancyClinical Reviews in Allergy & Immunology, 2022
- Global and regional circulation trends of norovirus genotypes and recombinants, 1995–2019: A comprehensive review of sequences from public databasesReviews in Medical Virology, 2022
- ABO blood group-associated susceptibility to norovirus infection: A systematic review and meta-analysisInfection, Genetics and Evolution, 2020
- Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccineVaccine, 2015
- Global prevalence of norovirus in cases of gastroenteritis: a systematic review and meta-analysisThe Lancet Infectious Diseases, 2014
- Advances in Norovirus BiologyCell Host & Microbe, 2014
- Genetic susceptibility to symptomatic norovirus infection in NicaraguaJournal of Medical Virology, 2009
- Norwalk virus infection associates with secretor status genotyped from seraJournal of Medical Virology, 2005
- Human susceptibility and resistance to Norwalk virus infectionNature Medicine, 2003
- Surrogate endpoints in clinical trials: Definition and operational criteriaStatistics in Medicine, 1989